Welcome
Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Latest News
2012-04-03
Ajinomoto Pharmaceuticals and Albireo Announce Japan and Asia License Agreement for Elobixibat
2011-12-21
INN for A3309 is ELOBIXIBAT
Go to news archive
Events
UEGW, Amsterdam, October 2012
DDW, San Diego, May 2012
JP Morgan, San Francisco, January 2012